Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold

<p>Abstract</p> <p>Background</p> <p>Common cold is caused by a variety of respiratory viruses. The prevalence in children is high, and it potentially contributes to significant morbidity. Iota-carragenan, a polymer derived from red seaweed, has reduced viral load in na...

Full description

Bibliographic Details
Main Authors: Fazekas Tamas, Eickhoff Philipp, Pruckner Nathalie, Vollnhofer Georg, Fischmeister Gustav, Diakos Christopher, Rauch Margit, Verdianz Maria, Zoubek Andreas, Gadner Helmut, Lion Thomas
Format: Article
Language:English
Published: BMC 2012-09-01
Series:BMC Complementary and Alternative Medicine
Subjects:
Online Access:http://www.biomedcentral.com/1472-6882/12/147
id doaj-29f4b7eed44c49f68351d5485abf3590
record_format Article
spelling doaj-29f4b7eed44c49f68351d5485abf35902020-11-25T02:19:34ZengBMCBMC Complementary and Alternative Medicine1472-68822012-09-0112114710.1186/1472-6882-12-147Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common coldFazekas TamasEickhoff PhilippPruckner NathalieVollnhofer GeorgFischmeister GustavDiakos ChristopherRauch MargitVerdianz MariaZoubek AndreasGadner HelmutLion Thomas<p>Abstract</p> <p>Background</p> <p>Common cold is caused by a variety of respiratory viruses. The prevalence in children is high, and it potentially contributes to significant morbidity. Iota-carragenan, a polymer derived from red seaweed, has reduced viral load in nasal secretions and alleviated symptoms in adults with common cold.</p> <p>Methods</p> <p>We have assessed the antiviral and therapeutic activity of a nasal spray containing iota-carrageenan in children with acute symptoms of common cold. A cohort of 153 children between 1–18 years (mean age 5 years), displaying acute symptoms of common cold were randomly assigned to treatment with a nasal spray containing iota-carrageenan (0.12%) as verum or 0.9% sodium chloride solution as placebo for seven days. Symptoms of common cold were recorded and the viral load of respiratory viruses in nasal secretions was determined at two consecutive visits.</p> <p>Results</p> <p>The results of the present study showed no significant difference between the iota carrageenan and the placebo group on the mean of TSS between study days 2–7. Secondary endpoints, such as reduced time to clearance of disease (7.6 vs 9.4 days; p = 0.038), reduction of viral load (p = 0.026), and lower incidence of secondary infections with other respiratory viruses (p = 0.046) indicated beneficial effects of iota-carrageenan in this population. The treatment was safe and well tolerated, with less side effects observed in the verum group compared to placebo.</p> <p>Conclusion</p> <p>In this study iota-carrageenan did not alleviate symptoms in children with acute symptoms of common cold, but significantly reduced viral load in nasal secretions that may have important implications for future studies.</p> <p>Trial registration</p> <p>ISRCTN52519535, <url>http://www.controlled-trials.com/ISRCTN52519535/</url></p> http://www.biomedcentral.com/1472-6882/12/147CarrageenanCommon coldViral infectionUpper respiratory tract infectionsPediatric pulmonology
collection DOAJ
language English
format Article
sources DOAJ
author Fazekas Tamas
Eickhoff Philipp
Pruckner Nathalie
Vollnhofer Georg
Fischmeister Gustav
Diakos Christopher
Rauch Margit
Verdianz Maria
Zoubek Andreas
Gadner Helmut
Lion Thomas
spellingShingle Fazekas Tamas
Eickhoff Philipp
Pruckner Nathalie
Vollnhofer Georg
Fischmeister Gustav
Diakos Christopher
Rauch Margit
Verdianz Maria
Zoubek Andreas
Gadner Helmut
Lion Thomas
Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
BMC Complementary and Alternative Medicine
Carrageenan
Common cold
Viral infection
Upper respiratory tract infections
Pediatric pulmonology
author_facet Fazekas Tamas
Eickhoff Philipp
Pruckner Nathalie
Vollnhofer Georg
Fischmeister Gustav
Diakos Christopher
Rauch Margit
Verdianz Maria
Zoubek Andreas
Gadner Helmut
Lion Thomas
author_sort Fazekas Tamas
title Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
title_short Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
title_full Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
title_fullStr Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
title_full_unstemmed Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
title_sort lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
publisher BMC
series BMC Complementary and Alternative Medicine
issn 1472-6882
publishDate 2012-09-01
description <p>Abstract</p> <p>Background</p> <p>Common cold is caused by a variety of respiratory viruses. The prevalence in children is high, and it potentially contributes to significant morbidity. Iota-carragenan, a polymer derived from red seaweed, has reduced viral load in nasal secretions and alleviated symptoms in adults with common cold.</p> <p>Methods</p> <p>We have assessed the antiviral and therapeutic activity of a nasal spray containing iota-carrageenan in children with acute symptoms of common cold. A cohort of 153 children between 1–18 years (mean age 5 years), displaying acute symptoms of common cold were randomly assigned to treatment with a nasal spray containing iota-carrageenan (0.12%) as verum or 0.9% sodium chloride solution as placebo for seven days. Symptoms of common cold were recorded and the viral load of respiratory viruses in nasal secretions was determined at two consecutive visits.</p> <p>Results</p> <p>The results of the present study showed no significant difference between the iota carrageenan and the placebo group on the mean of TSS between study days 2–7. Secondary endpoints, such as reduced time to clearance of disease (7.6 vs 9.4 days; p = 0.038), reduction of viral load (p = 0.026), and lower incidence of secondary infections with other respiratory viruses (p = 0.046) indicated beneficial effects of iota-carrageenan in this population. The treatment was safe and well tolerated, with less side effects observed in the verum group compared to placebo.</p> <p>Conclusion</p> <p>In this study iota-carrageenan did not alleviate symptoms in children with acute symptoms of common cold, but significantly reduced viral load in nasal secretions that may have important implications for future studies.</p> <p>Trial registration</p> <p>ISRCTN52519535, <url>http://www.controlled-trials.com/ISRCTN52519535/</url></p>
topic Carrageenan
Common cold
Viral infection
Upper respiratory tract infections
Pediatric pulmonology
url http://www.biomedcentral.com/1472-6882/12/147
work_keys_str_mv AT fazekastamas lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT eickhoffphilipp lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT prucknernathalie lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT vollnhofergeorg lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT fischmeistergustav lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT diakoschristopher lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT rauchmargit lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT verdianzmaria lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT zoubekandreas lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT gadnerhelmut lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
AT lionthomas lessonslearnedfromadoubleblindrandomisedplacebocontrolledstudywithaiotacarrageenannasalsprayasmedicaldeviceinchildrenwithacutesymptomsofcommoncold
_version_ 1724875930805993472